|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 8 (October 15), 1999:
pp. 2911-2914
Correlation Between Disparity for the Minor Histocompatibility Antigen
HA-1 and the Development of Acute Graft-Versus-Host Disease After
Allogeneic Marrow Transplantation
Li-Hui Tseng,
Ming-Tseh Lin,
John A. Hansen,
Ted Gooley,
Ji Pei,
Anajane G. Smith,
Emily G. Martin,
Effie W. Petersdorf, and
Paul J. Martin
From the Division of Clinical Research, Fred Hutchinson Cancer
Research Center, Seattle, WA; the Department of Medical Genetics and
Oncology, National Taiwan University Hospital, Taipei, Taiwan; and the
Department of Internal Medicine, University of Washington,
Seattle, WA.
Results of a previous study suggested that recipient mismatching for
the minor histocompatibility antigen HA-1 is associated with acute
graft-versus-host disease (GVHD) after allogeneic marrow transplantation. In that study, most patients received either cyclosporine or methotrexate for GVHD prophylaxis, and a cytotoxic T-cell clone was used to test for HA-1 disparity. To facilitate large-scale testing, we developed a method that uses genomic DNA to
identify HA-1 alleles. A retrospective study was conducted to correlate
HA-1 disparity and the occurrence of acute GVHD in 237 HLA-A2-positive
white patients who had received a marrow or peripheral blood stem cell
transplant from an HLA-identical sibling. All patients received both
methotrexate and cyclosporine for GVHD prophylaxis. The presence of
HLA-A*0201 was confirmed in 34 of the 36 HA-1 disparate pairs by
sequencing the HLA-A locus. Grades II-IV GVHD occurred in 22 (64.7%)
of these 34 patients, compared with 86 (42.8%) of the 201 patients
without HA-1 disparity (odds ratio, 2.45; 95% confidence interval
[CI], 1.15 to 5.23; P = .02). Recipient HA-1 disparity
showed a trend for association with acute GVHD (odds ratio, 2.1; 95%
CI, 0.91 to 4.68; P = .08) when a multivariable logistic
regression model was used to include additional risk factors. These
data are consistent with results of the previous study, suggesting an
association between HA-1 disparity and risk of acute GVHD, but the
strength of this association may be lower in patients who received both
methotrexate and cyclosporine than in those who received methotrexate
or cyclosporine alone.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Absence of statistically significant correlation between disparity for the minor histocompatibility antigen HA-1 and outcome after allogeneic hematopoietic cell transplantation
- Ming-Tseh Lin, Ted Gooley, John A. Hansen, Li-Hui Tseng, Emily G. Martin, Kentner Singleton, Anajane G. Smith, Eric Mickelson, Effie W. Petersdorf, and Paul J. Martin
Blood 2001 98: 3172-3173.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Mullally and J. Ritz
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation
Blood,
February 15, 2007;
109(4):
1355 - 1362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Torikai, Y. Akatsuka, M. Miyazaki, E. H. Warren III, T. Oba, K. Tsujimura, K. Motoyoshi, Y. Morishima, Y. Kodera, K. Kuzushima, et al.
A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene
J. Immunol.,
December 1, 2004;
173(11):
7046 - 7054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dorrschuck, A. Schmidt, E. Schnurer, M. Gluckmann, C. Albrecht, C. Wolfel, V. Lennerz, A. Lifke, C. Di Natale, E. Ranieri, et al.
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression
Blood,
October 15, 2004;
104(8):
2591 - 2599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. James, J.-G. Chai, H. Dewchand, E. Macchiarulo, F. Dazzi, and E. Simpson
Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans
Blood,
July 1, 2003;
102(1):
388 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Y. Choi, G. J. Christianson, Y. Yoshimura, N. Jung, T. J. Sproule, S. Malarkannan, S. Joyce, and D. C. Roopenian
Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease
Blood,
December 15, 2002;
100(13):
4259 - 4264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zorn, K. S. Wang, E. P. Hochberg, C. Canning, E. P. Alyea, R. J. Soiffer, and J. Ritz
Infusion of CD4+ Donor Lymphocytes Induces the Expansion of CD8+ Donor T Cells with Cytolytic Activity Directed against Recipient Hematopoietic Cells
Clin. Cancer Res.,
July 1, 2002;
8(7):
2052 - 2060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. M. den Haan, T. Mutis, E. Blokland, A. P. IJzerman, and E. Goulmy
General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responses
Blood,
February 1, 2002;
99(3):
985 - 992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-T. Lin, T. Gooley, J. A. Hansen, L.-H. Tseng, E. G. Martin, K. Singleton, A. G. Smith, E. Mickelson, E. W. Petersdorf, and P. J. Martin
Absence of statistically significant correlation between disparity for the minor histocompatibility antigen HA-1 and outcome after allogeneic hematopoietic cell transplantation
Blood,
November 15, 2001;
98(10):
3172 - 3173.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Y. Choi, Y. Yoshimura, G. J. Christianson, T. J. Sproule, S. Malarkannan, N. Shastri, S. Joyce, and D. C. Roopenian
Quantitative Analysis of the Immune Response to Mouse Non-MHC Transplantation Antigens In Vivo: The H60 Histocompatibility Antigen Dominates Over All Others
J. Immunol.,
April 1, 2001;
166(7):
4370 - 4379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Storb, R. Champlin, S. R. Riddell, M. Murata, S. Bryant, and E. H. Warren
Non-Myeloablative Transplants for Malignant Disease
Hematology,
January 1, 2001;
2001(1):
375 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
